

UK FORUM ON HAEMOGLOBIN DISORDERS

England & Wales · Charity number 1163743

Details

Status Registered

Legal form Charitable company

Company number [09481209](#)

Registered 2015-09-28

Register [View on the Charity Commission register](#)

Contact

Address Department Of Haematology
Guys Hospital
Great Maze Pond
London
SE1 9RT

Phone 02071882741

Email Rachel.Kesse-Adu@gstt.nhs.uk

Website <https://haemoglobin.org.uk>

Activities

Objects: THE CHARITY'S OBJECTS ARE SPECIFICALLY RESTRICTED TO THE ADVANCEMENT OF HEALTH FOR THE PUBLIC BENEFIT BY PROMOTING CARE FOR THOSE WITH HAEMOGLOBIN DISORDERS AND STUDY AND RESEARCH IN HAEMOGLOBIN DISORDERS AND THE PUBLICATION OF THE USEFUL RESULTS OF SUCH RESEARCH.

Activities: The charity's objects are the advancement of health for the public benefit by promoting high quality care for those with haemoglobin disorders, by undertaking educational activities for healthcare professionals, and by involvement in quality reviews and quality assessments of aspects of care in provider hospitals and community services.

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups

Geography

- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£41,290	£73,582	-	-
2024-03-31	£44,145	£49,246	-	-
2023-03-31	£49,336	£49,210	-	-
2022-03-31	£32,541	£25,702	-	-
2021-03-31	£43,576	£31,273	-	-

Trustees

Name	Role	Appointed
Dr Rachel Kesse-Adu	Chair	2019-05-01
Annette Blackmore		2023-03-08
Dr Asad Luqmani		2023-03-08
Dr MARY PETROU		2015-03-10
Dr Ruth Anderson		2023-03-08
Dr Subarna Chakravorty		2019-05-01

UK FORUM ON HAEMOGLOBIN DISORDERS

England & Wales - Charity number 1163743

Accounts

Company registration number 09481209 (England and Wales)

Charity registration number 1163743 (England and Wales)

**UK FORUM ON HAEMOGLOBIN DISORDERS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

UK FORUM ON HAEMOGLOBIN DISORDERS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Dr Mary Petrou (Treasurer)
Dr Rachel Kesse-Adu
Dr Subarna Chakravorty
Dr A Luqmani
Dr R Anderson
A Blackmore

Charity number

1163743

Company number

09481209

Registered office

Galla House
695 High Road
North Finchley
London
N12 0BT

Accountants

Lyons Leonidou
Galla House
695 High Road
North Finchley
London
N12 0BT

Bankers

National Westminster Bank Plc
Queen Street Branch
96 Queen Street
Cardiff
CF10 2GR

UK FORUM ON HAEMOGLOBIN DISORDERS

CONTENTS

	Page
Trustees' report	1 - 4
Accountants' report	5
Statement of financial activities	6
Balance sheet	7
Notes to the financial statements	8 - 13

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2025

The trustees (who are also directors of the charity for the purposes of the Companies Act) present their report and accounts for the year ended 31 March 2025.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

Objectives and activities

The charity's objects are specifically restricted to the advancement of health for the public benefit by promoting care for those with haemoglobin disorders and study and research in haemoglobin disorders and the publication of useful results.

The charity will continue to provide peer review and conduct courses for the advancement of the health profession on the subject of the blood disorders, sickle cell disease and thalassaemia.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The charity undertook the following activities:

Peer Review

The UKFHD contributed £45,000 and VAT towards the costs of the peer review program led by Dr Emma Drašar, which commenced on 17th October 2024 at Sheffield Teaching Hospital NHS Foundation Trust, and is due to be completed with a final visit on 12th September 2025 at Barking and Havering NHS Foundation Trusts at Queens Hospital in Romford. Review aims to attend all SHTs and HCCs in England. Host Trusts are directly invoiced for the remainder of the costs of the review including support for clinical leads to write the peer review reports, at £5,900 per service.

For each visit, the review teams complete a pre-visit review of submitted evidence from the specialist haemoglobinopathy and coordinating centre teams. This evidence assessment is completed virtually, before the physical visit to the Hospital site is undertaken. The administration/logistic support for the peer review programme was contracted to, and is undertaken by an external company, NHS Midlands and Lancashire, led by Ms Sarah Broomhead, Professional Lead for Nursing and Urgent Care Directorate.

Educational meetings

We continued to organise 2 academic meetings per year, in 2024 these were held:

8th May 2024, the 57th Educational meeting was held at the IET in Birmingham, this was originally planned to be an in person only meeting but then had to be changed last minute to a hybrid meeting due to industrial action on the railways. The meeting was organised, as usual in partnership with the Hartley Taylor team LTD (04029300).

The morning sessions focused on a case presentation from a resident doctor colleague, then a talk on gene therapy from Prof de la Fuente of Imperial College, London, followed by a talk on fertility preservation by Dr Vikram Talaulikar of UCH London. Then we had a vibrant and interactive round table with transplant colleagues; Dr Ben Carpenter, Dr Beki James and Dr Subarna Chakravorty, as well as red cell colleagues Dr Amy Webster, and Dr Perla Elftheriou and Ms Roanna Maharaj as a patient representative. The round table focused on the current pathways for curative therapies and gene therapy, indications, concerns and outcome. There was an update from the patient societies and the afternoon session chaired by Dr Kate Gardner focused on ageing in haemoglobinopathies, with talks from Dr Shivan Pancham, Dr Kate Gardner, Psychologist Dr Ruth Anderson and Frailty physician Dr Huma Naqvi from Birmingham and Sandwell Hospitals.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2025

19th Nov 2024: The 58th Educational meeting was a hybrid meeting with in person and a virtual audience, we continued the successful in partnership with the Hartley Taylor team LTD and the meeting was held at the Cavendish Conference centre. The morning session chaired by Dr Mary Petrou had an update from colleagues in Scotland on haemoglobinopathy there, we celebrated colleagues who have left the NHS, Dr Samah Babiker presented for Prof Inusa who has retired and moved into industry, Dr Clare Samuelson presented on behalf of Dr Josh Wright and Dr Emma Drasar on behalf of Dr Farrukh Shah who was the preceding Chair of the UK Forum. There were also presentations on the role of dietetics from Dr Claudine Matthes, Endocrinology in Thalassaemia by Dr Julian Waung. The afternoon sessions had presentations from Prof Noemi Roy on NEQAS, then we focused on strokes in adults with presentations by Dr Paul Holmes, Dr Anupama Krishnamoorthi (a case study) and Mr Cristos Toliias. Then we concluded with a CRG update and the launch of the new RCN Nursing competencies.

There was an additional symposium from Vertex on Gene Therapy, which members could elect to stay on for at the close of the day.

Both academic meetings had engagement from more than 100 attendees with excellent feedback.

Trustee and committee meetings

After November 2024, we moved two of the trustee and committee meetings to coincide with the educational meetings, aiming to encourage in person attendance, these were scheduled in the hour preceding the academic meetings. Additional committee meetings over MSTeams were held in June, and September 2024.

Liaison and attendance with other committees (feedback to Trustees via rolling agenda)

National Screening Committee: we had new members joining the committee for the antenatal and neonatal screening programme for haemoglobinopathies.

National Haemoglobinopathy Registry: Prof Noemi Roy was added to attendance after departure of Dr Farrukh Shah to support the work of the NHR.

Clinical Reference Group for Haemoglobinopathies: Dr Subarna Chakravorty who is a trustee as well as the CRG chair represented the CRG to update on the work of that group.

We added regular representation from colleagues from Scotland – Dr Fernando Pinto and Dr Louisa McIlwaine, we had continued representation from Wales with Dr Indu Thakur and Ms Annette Blackmore. Northern Ireland representation from Colleen Williamson

Research

The red cell collaborative research group was originally represented by Dr Paul Telfer, however his attendance tailed off after his resignation from the committee as a trustee, a new member – Dr Sanne Lugthart was co-opted to keep the committee updated.

Achievements and performance

We remained a key stake holder for NICE submissions and were actively involved in the ultimately successful, Casgevy submissions for both sickle cell and Thalassaemia.

We appointed a lead clinician and continued to support the organisation, implementation and active involvement of the clinical community in the haemoglobinopathies peer review program.

We continued to hold the twice-yearly academic sessions which have both excellent attendance and feedback as noted above, topics are selected from a combination of issues raised via the NHP and from attendee feedback.

We started an initiative to extend invitation to trainees to attend our Education days free of charge to encourage interest in the field.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) *FOR THE YEAR ENDED 31 MARCH 2025*

Financial review

The principal source of funding is from voluntary donations from individual and other organisations.

The principal source of funding is from applications for independent funding grants from industry partners aimed at our education days, voluntary donations and membership dues.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six-month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution. It will also try to increase the incoming level of donation.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2025

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 10th March 2015 and registered as charity on 28th September 2015 with Registered Charity No 11633743. The company was established under Memorandum of Association, which established the objects and powers of the charitable company and is governed under its Articles of Association. Dr Fernando Pinto and Dr Louisa McIlwaine have joined committee as representatives of Scotland.

The trustees and who served during the year and subsequently were:

Dr Mary Petrou (Treasurer)

Dr Farrukh Shah

(Resigned 28 April 2024)

Dr Rachel Kesse-Adu

Dr Subarna Chakravorty

Dr A Luqmani

Dr R Anderson

A Blackmore

The trustees are selected for their understanding and sympathy with the aim and objectives of the charity, and have confirmed they are prepared to offer their time and expertise to support it.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity does not provide the trustees with any indemnity insurance.

The trustees meet on a regular basis to agree the strategic direction and the policy of the charity. One of the trustee is responsible for the day to day administration to ensure that the charity can deliver timely and efficient service.

There are no connected charities.

The trustees' report was approved by the Board of Trustees.



Dr Mary Petrou (Treasurer)

Trustee

Dated: 12 March 2026

UK FORUM ON HAEMOGLOBIN DISORDERS

CHARTERED ACCOUNTANT ACCOUNTANTS' REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of UK Forum on Haemoglobin Disorders for the year ended 31 March 2025, which comprise the statement of financial activities and the related notes from the charity's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at <https://www.icaew.com/regulation>.

This report is made to the charity's trustees, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of UK Forum on Haemoglobin Disorders and state those matters that we have agreed to state to the charity's trustees, as a body, in this report in accordance with ICAEW Technical Release 07/16. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than UK Forum on Haemoglobin Disorders and the charity's trustees as a body, for our work or for this report.

It is your duty to ensure that UK Forum on Haemoglobin Disorders has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and deficit of UK Forum on Haemoglobin Disorders. You consider that UK Forum on Haemoglobin Disorders is exempt from the statutory audit requirement for the year, and is not required to obtain an independent examiner's report.

We have not been instructed to carry out an audit or a review of the financial statements of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Lyons Leonidou
Chartered Accountant Accountants

13 March 2026

Galla House
695 High Road
North Finchley
London
N12 0BT

UK FORUM ON HAEMOGLOBIN DISORDERS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Income from:							
Donations and legacies	3	2,629	-	2,629	1,150	-	1,150
Charitable activities	4	38,500	-	38,500	42,844	-	42,844
Investments	5	161	-	161	151	-	151
Total income		41,290	-	41,290	44,145	-	44,145
Expenditure on:							
<u>Charitable activities</u>	6	46,582	27,000	73,582	49,246	27,000	76,246
Total expenditure		46,582	27,000	73,582	49,246	27,000	76,246
Net expenditure		(5,292)	(27,000)	(32,292)	(5,101)	(27,000)	(32,101)
Transfers between funds		(56,650)	56,650	-	-	-	-
Net movement in funds		(61,942)	29,650	(32,292)	(5,101)	(27,000)	(32,101)
Reconciliation of funds:							
Fund balances at 1 April 2024		158,898	99,505	258,403	163,999	126,505	290,504
Fund balances at 31 March 2025		96,956	129,155	226,111	158,898	99,505	258,403

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

UK FORUM ON HAEMOGLOBIN DISORDERS

BALANCE SHEET

AS AT 31 MARCH 2025

	Notes	2025 £	£	2024 £	£
Current assets					
Cash at bank and in hand		228,307		260,599	
Creditors: amounts falling due within one year	11	(2,196)		(2,196)	
Net current assets			<u>226,111</u>		<u>258,403</u>
The funds of the charity					
Restricted income funds	12		129,155		99,505
Unrestricted funds	13		96,956		158,898
			<u>226,111</u>		<u>258,403</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2025.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 12 March 2026


Dr Mary Petrou (Treasurer)
Trustee

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

Charity information

UK Forum on Haemoglobin Disorders is a private company limited by guarantee incorporated in England and Wales. The registered office is Galla House, 695 High Road, North Finchley, London, N12 0BT.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.5 Resources expended

Resources expended on charitable expenditure comprise in meeting the charitable objective. Such cost includes direct cost of the charitable activities together with those identifiable support cost incurred that enable these activities to be undertaken.

Governance cost and support cost are cost incurred for the management and administration of the Charity. These cost are incurred so that the Charity can operate and meet its statutory and constitutional obligation.

Support cost is allocated where appropriate to an activity based on use of resource. Staff cost where appropriate has been allocated on a consistent basis.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.7 General Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees to further the objectives of the Charity. Investment income and gains are allocated to unrestricted funds.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and subscriptions

	2025	2024
	£	£
Membership fees	2,629	1,150
	<u>2,629</u>	<u>1,150</u>

4 Income from charitable activities

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Heading #ac989		
Sale of goods	38,500	42,844
	<u>38,500</u>	<u>42,844</u>

5 Income from investments

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Interest receivable	161	151
	<u>161</u>	<u>151</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

6 Expenditure on charitable activities

	2025 £	2024 £
Direct costs		
Course costs - Hiring hall, catering and lecturers fees	70,777	73,838
Share of support and governance costs (see note 7)		
Governance	2,805	2,408
	<u>73,582</u>	<u>76,246</u>
Analysis by fund		
Unrestricted funds	46,582	49,246
Restricted funds	27,000	27,000
	<u>73,582</u>	<u>76,246</u>

7 Support costs

	Support costs £	Governance costs £	2025 £	2024 £
Legal and professional	-	2,196	2,196	2,196
General expense	-	609	609	212
	<u>-</u>	<u>2,805</u>	<u>2,805</u>	<u>2,408</u>
Analysed between				
Charitable activities	<u>-</u>	<u>2,805</u>	<u>2,805</u>	<u>2,408</u>

Governance costs includes Accountancy fees of £2,196 (2022 £2,125).

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year or previous year, None of the trustees were reimbursed any expenses during current year or previous year.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

9 Employees

The average monthly number of employees during the year was:

2025 Number	2024 Number
6	8
<u>6</u>	<u>8</u>

There were no paid employees in the year.

10 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

11 Creditors: amounts falling due within one year

	2025 £	2024 £
Accruals	2,196	2,196
	<u>2,196</u>	<u>2,196</u>

12 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations held on trust for specific purposes:

	At 1 April 2024 £	Resources expended £	Transfers £	At 31 March 2025 £
	99,505	(27,000)	56,650	129,155
	<u>99,505</u>	<u>(27,000)</u>	<u>56,650</u>	<u>129,155</u>
Previous year:				
	At 1 April 2023 £	Resources expended £	Transfers £	At 31 March 2024 £
	126,505	(27,000)	-	99,505
	<u>126,505</u>	<u>(27,000)</u>	<u>-</u>	<u>99,505</u>

Restricted funds should be applied for quality peer review programme and work on quality assurances for brain vessel scans for children with sickle cell disease.

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 April 2024 £	Incoming resources £	Resources expended £	Transfers £	At 31 March 2025 £
General funds	158,898	41,290	(46,582)	(56,650)	96,956
	<u>158,898</u>	<u>41,290</u>	<u>(46,582)</u>	<u>(56,650)</u>	<u>96,956</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

13 Unrestricted funds (Continued)

Previous year:	At 1 April 2023	Incoming resources	Resources expended	Transfers	At 31 March 2024
	£	£	£	£	£
General funds	163,999	44,145	(49,246)	-	158,898

14 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total
	£	£	£
Fund balances at 31 March 2025 are represented by:			
Current assets	96,956	129,155	226,111
	96,956	129,155	226,111

UK FORUM ON HAEMOGLOBIN DISORDERS

England & Wales - Charity number 1163743

Accounts

Charity registration number 1163743 (England and Wales)

Company registration number 09481209

**UK FORUM ON HAEMOGLOBIN DISORDERS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

UK FORUM ON HAEMOGLOBIN DISORDERS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Dr Baba Inusa Dr Mary Petrou Dr Farrukh Shah (Chairwoman) Mrs Karen Madgwick (Secretary) Dr Rachel Kesse-Adu (Treasurer) Dr Subarna Chakravorty Dr A Lugmani Dr R Anderson A Blackmore
Charity number	1163743
Company number	09481209
Registered office	Galla House 695 High Road North Finchley London N12 0BT
Accountants	Lyons Leonidou Galla House 695 High Road North Finchley London N12 0BT
Bankers	National Westminster Bank Plc Queen Street Branch 96 Queen Street Cardiff CF10 2GR

UK FORUM ON HAEMOGLOBIN DISORDERS

CONTENTS

	Page
Trustees' report	1 - 4
Accountants' report	5
Statement of financial activities	6
Balance sheet	7
Notes to the financial statements	8 - 13

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2024

The trustees (who are also directors of the charity for the purposes of the Companies Act) present their report and accounts for the year ended 31 March 2024.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

Objectives and activities

The charity's objects are specifically restricted to the advancement of health for the public benefit by promoting care for those with haemoglobin disorders and study and research in haemoglobin disorders and the publication of useful results.

The charity will continue to provide peer review and conduct courses for the advancement of the health profession on the subject of the blood disorders, sickle cell disease and thalassaemia.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2024

The charity undertook the following activities:

Peer Review

The UKFHD contributed £45,000 and VAT towards the costs of the current and ongoing peer review program led by Dr Emma Drašar. Host Trusts were directly invoiced for the remainder of the costs of review including support for clinical leads to write the peer review reports at £5,900 per service. The review program has continued at pace, since 17th October 2023 when the first visit at Sheffield Teaching Hospital NHS Foundation Trust was successfully completed. Reviews are planned for all Specialist Haemoglobinopathy teams (SHTs) and Haemoglobinopathy Coordinating Centres (HCCs). As of March 2024, 18 visits to SHTs (total of 11 trusts) were completed.

For each visit, the review team completes a pre-visit review of submitted evidence from the specialist haemoglobinopathy and coordinating centre teams. This evidence assessment is completed virtually, before the physical visit to the Hospital site is undertaken. The administration/logistic support for the peer review programme is contracted to, and continues to be provided by an external company, NHS Midlands and Lancashire, led by Ms Sarah Broomhead, Professional Lead for Nursing and Urgent Care Directorate.

The onsite visits by peer reviewers commenced on 17th October 2023 at Sheffield Teaching Hospital NHS Foundation Trust and is expected continue with the last visit due to be completed in June 2025. For each visit, the review team completes a pre-visit review of submitted evidence from the specialist haemoglobinopathy and coordinating centre teams. This evidence assessment is completed virtually, before the physical visit to the Hospital site is undertaken. The administration/logistic support for the peer review program is contracted to, and continues to be provided by an external company, NHS Midlands and Lancashire Commissioning Support Unit, led by Ms Sarah Broomhead, Professional lead for Nursing and Urgent care directorate. The physical inspection of sites commenced on 17th October 2023 at Sheffield and is expected continue with the last visit due to be completed in Spring 2025

Educational meetings

We continue to organise 2 academic meetings per year, in 2023 these were held:

May 2023: 55th Educational Meeting: held on 3rd May 2023, it was a hybrid meeting with in person attendance as well as a virtual audience. The meeting was organised in partnership with the Hartley Taylor team LTD (04029300) to provide educational meeting and secretarial support. The morning focused on transfusion, and included an international speaker Dr Shirley Owusu Ofori, lead of the National Blood Service of Ghana. We acknowledged and gave thanks to Dr Lola Oni who has retired. Then a high-level presentation of transfusion cases discussed at the NHP, a difficult to transfuse case presentation and then an MDT panel discussion was had on the challenges and evidence for our current practice. The afternoon focused on a patient's and then a psychologists perspective on transfusions, the final sessions were focused on vascular access with a presentation from the UKTS and a renal vascular surgeon on the use of arterio-venous fistulae for exchange transfusion and the final item was a soft launch of the UKTS Thalassaemia standards.

Nov 2023: The 56th meeting was held on Wednesday 22nd November, this was also a hybrid meeting with in person and a virtual audience, we continued the successful in partnership with the Hartley Taylor team LTD. It was held at the Cavendish Conference centre. The morning focused on renal transplant in sickle cell, the role of transfusion and HLA sensitisation in SCD patients. A memorial was held to acknowledge the sudden, unexpected loss of committee member Melanie Percy. The late morning session focused on Medtech funding, screening for haemoglobinopathies and the nurse consultant role in practice. The afternoon session was on pain management with a case presentation, a psychologist's perspective on pain management and an update from the acute pain group.

Both academic meetings had excellent feedback from attendees.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2024

Trustee and committee meetings

3 trustee / committee meetings were held in June, September, November 2023.

Liaison and attendance with other committees (feedback to Trustees via rolling agenda)

National Screening Committee: committee members attended quarterly meetings. This committee promotes the antenatal and neonatal screening programme for haemoglobinopathies.

National Haemoglobinopathy Registry: committee members attended the quarterly steering group meetings till to support the work of the NHR.

Clinical Reference Group for Haemoglobinopathies: co-opted committee members attended meetings to represent the views of health professionals in the development of services for patients with Haemoglobinopathies.

UKFHD Chair is also a co-opted member of the Clinical reference group (CRG) and attends those committee meetings.

Research

Committee members attend the meeting of the non-malignant clinical research network (CRN). Attendance of the research subgroup as a collaborative group with colleagues nationally tailed off during the course of the year and a new member was co-opted to attend – Dr Sanne Lugthart to keep the committee updated.

Achievements and performance

The organisation of the peer review program, the academic sessions as well as our active involvement engagement with other organisations, including NICE with our organisation recognised as a key in submissions on new agents and technologies directed at patients including gene therapy for thalassaemia and sickle cell as well as contributing to the appeal for Voxelotor. Another achievement is the committee now has representation from all the devolved nations.

Financial review

The principal source of funding is from voluntary donations from individual and other organisations.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution. It will also try to increase the incoming level of donation.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2024

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 10th March 2015 and registered as charity on 28th September 2015 with Registered Charity No 11633743. The company was established under Memorandum of Association, which established the objects and powers of the charitable company and is governed under its Articles of Association. Dr Fernando Pinto and Dr Louisa McIlwaine have joined committee as representatives of Scotland. Dr Farrukh Shah has submitted her resignation as chair in November 2023 and completed her term in March 2024. Dr Melanie Percy, Clinical scientist and member of the committee sadly died July 2023.

The trustees and who served during the year and subsequently were:

Dr Baba Inusa

Dr Mary Petrou

Dr Farrukh Shah (Chairwoman)

Mrs Karen Madgwick (Secretary)

Dr Rachel Kesse-Adu (Treasurer)

Dr Subarna Chakravorty

Dr A Lugmani

Dr R Anderson

A Blackmore

The trustees are selected for their understanding and sympathy with the aim and objective of the charity, who are prepared to offer their time and expertise to support it.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity does not provide the trustees with any indemnity insurance.

The trustees meet on a regular basis to agree the strategic direction and the policy of the charity. One of the trustee is responsible for the day to day administration to ensure that the charity can deliver timely and efficient service.

There are no connected charities.

The trustees' report was approved by the Board of Trustees.

Dr Rachel Kesse-Adu (Treasurer)

Trustee

Dated: 20 December 2024

UK FORUM ON HAEMOGLOBIN DISORDERS

CHARTERED ACCOUNTANT ACCOUNTANTS' REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of UK Forum on Haemoglobin Disorders for the year ended 31 March 2024, which comprise the statement of financial activities and the related notes from the charity's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at <https://www.icaew.com/regulation>.

This report is made to the charity's trustees, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of UK Forum on Haemoglobin Disorders and state those matters that we have agreed to state to the charity's trustees, as a body, in this report in accordance with ICAEW Technical Release 07/16. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than UK Forum on Haemoglobin Disorders and the charity's trustees as a body, for our work or for this report.

It is your duty to ensure that UK Forum on Haemoglobin Disorders has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and deficit of UK Forum on Haemoglobin Disorders. You consider that UK Forum on Haemoglobin Disorders is exempt from the statutory audit requirement for the year, and is not required to obtain an independent examiner's report.

We have not been instructed to carry out an audit or a review of the financial statements of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Lyons Leonidou
Chartered Accountant Accountants

21 December 2024

Galla House
695 High Road
North Finchley
London
N12 0BT

UK FORUM ON HAEMOGLOBIN DISORDERS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2024

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Income from:							
Donations and legacies	3	1,150	-	1,150	2,037	-	2,037
Charitable activities	4	42,844	-	42,844	47,250	-	47,250
Investments	5	151	-	151	49	-	49
Total income		<u>44,145</u>	<u>-</u>	<u>44,145</u>	<u>49,336</u>	<u>-</u>	<u>49,336</u>
Expenditure on:							
<u>Charitable activities</u>	6	<u>49,246</u>	<u>27,000</u>	<u>76,246</u>	<u>49,210</u>	<u>-</u>	<u>49,210</u>
Total expenditure		<u>49,246</u>	<u>27,000</u>	<u>76,246</u>	<u>49,210</u>	<u>-</u>	<u>49,210</u>
Net income/(expenditure) and movement in funds		(5,101)	(27,000)	(32,101)	126	-	126
Reconciliation of funds:							
Fund balances at 1 April 2023		<u>163,999</u>	<u>126,505</u>	<u>290,504</u>	<u>163,873</u>	<u>126,505</u>	<u>290,378</u>
Fund balances at 31 March 2024		<u>158,898</u>	<u>99,505</u>	<u>258,403</u>	<u>163,999</u>	<u>126,505</u>	<u>290,504</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

UK FORUM ON HAEMOGLOBIN DISORDERS

BALANCE SHEET

AS AT 31 MARCH 2024

	Notes	2024 £	£	2023 £	£
Current assets					
Cash at bank and in hand		260,600		292,700	
Creditors: amounts falling due within one year	11	<u>(2,196)</u>		<u>(2,196)</u>	
Net current assets			<u>258,404</u>		<u>290,504</u>
The funds of the charity					
Restricted income funds	12		99,505		126,505
Unrestricted funds	13		<u>158,898</u>		<u>163,999</u>
			<u>258,403</u>		<u>290,504</u>
Warning: Support and governance cost to reallocate (5000 codes must balance to nil to balance BS)			(1)		-
Warning: Balance sheet net assets do not equal equity, or there is a suspense balance.			(1)		-

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 20 December 2024

Dr Rachel Kesse-Adu (Treasurer)
Trustee

Company registration number 09481209 (England and Wales)

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

Charity information

UK Forum on Haemoglobin Disorders is a private company limited by guarantee incorporated in England and Wales. The registered office is Galla House, 695 High Road, North Finchley, London, N12 0BT.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

(Continued)

1.5 Resources expended

Resources expended on charitable expenditure comprise in meeting the charitable objective. Such cost includes direct cost of the charitable activities together with those identifiable support cost incurred that enable these activities to be undertaken.

Governance cost and support cost are cost incurred for the management and administration of the Charity. These cost are incurred so that the Charity can operate and meet its statutory and constitutional obligation.

Support cost is allocated where appropriate to an activity based on use of resource. Staff cost where appropriate has been allocated on a consistent basis.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.7 General Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees to further the objectives of the Charity. Investment income and gains are allocated to unrestricted funds.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and subscriptions

	2024	2023
	£	£
Membership fees	1,150	2,037
	<u>1,150</u>	<u>2,037</u>

4 Income from charitable activities

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Heading #ac989		
Sale of goods	42,844	47,250
	<u>42,844</u>	<u>47,250</u>

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	151	49
	<u>151</u>	<u>49</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

6 Expenditure on charitable activities

	2024 £	2023 £
Direct costs		
Course costs - Hiring hall, catering and lecturers fees	73,838	46,471
Share of support and governance costs (see note 7)		
Governance	2,408	2,739
	<u>76,246</u>	<u>49,210</u>
Analysis by fund		
Unrestricted funds	49,246	49,210
Restricted funds	27,000	-
	<u>76,246</u>	<u>49,210</u>

7 Support costs

	Support costs £	Governance costs £	2024 £	2023 £
Legal and professional	-	2,196	2,196	2,196
General expense	-	212	212	543
	<u>-</u>	<u>2,408</u>	<u>2,408</u>	<u>2,739</u>
Analysed between				
Charitable activities	<u>-</u>	<u>2,408</u>	<u>2,408</u>	<u>2,739</u>

Governance costs includes Accountancy fees of £2,196 (2022 £2,125).

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year or previous year, None of the trustees were reimbursed any expenses during current year or previous year.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

9 Employees

The average monthly number of employees during the year was:

2024 Number	2023 Number
8	8

There were no paid employees in the year.

10 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

11 Creditors: amounts falling due within one year

	2024 £	2023 £
Accruals	2,196	2,196

12 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations held on trust for specific purposes:

	At 1 April 2023 £	Resources expended £	At 31 March 2024 £
	126,505	(27,000)	99,505
Previous year:	At 1 April 2022 £	Resources expended £	At 31 March 2023 £
	126,505	-	126,505

Restricted funds should be applied for quality peer review programme and work on quality assurances for brain vessel scans for children with sickle cell disease.

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 April 2023 £	Incoming resources £	Resources expended £	At 31 March 2024 £
General funds	163,999	44,145	(49,246)	158,898

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

13 Unrestricted funds (Continued)

Previous year:	At 1 April 2022	Incoming resources	Resources expended	At 31 March 2023
	£	£	£	£
General funds	163,873	49,336	(49,210)	163,999
	<u>163,873</u>	<u>49,336</u>	<u>(49,210)</u>	<u>163,999</u>

14 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total
	£	£	£
Fund balances at 31 March 2024 are represented by:			
Current assets	258,404	-	258,404
	<u>258,404</u>	<u>-</u>	<u>258,404</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

England & Wales - Charity number 1163743

Accounts

Charity registration number 1163743

Company registration number 09481209 (England and Wales)

UK FORUM ON HAEMOGLOBIN DISORDERS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

UK FORUM ON HAEMOGLOBIN DISORDERS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Dr Baba Inusa Dr Mary Petrou Dr Farrukh Shah (Chairwoman) Mrs Karen Madgwick (Secretary) Dr Rachel Kesse-Adu (Treasurer) Dr Subarna Chakravorty Dr A Lugmani (Appointed 8 March 2023) Dr R Anderson (Appointed 8 March 2023) A Blackmore (Appointed 8 March 2023)
Charity number	1163743
Company number	09481209
Registered office	Galla House 695 High Road North Finchley London N12 0BT
Accountants	Lyons Leonidou Galla House 695 High Road North Finchley London N12 0BT
Bankers	National Westminster Bank Plc Queen Street Branch 96 Queen Street Cardiff CF10 2GR

UK FORUM ON HAEMOGLOBIN DISORDERS

CONTENTS

	Page
Trustees' report	1 - 3
Accountants' report	4
Statement of financial activities	5
Balance sheet	6
Notes to the financial statements	7 - 12

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2023

The trustees (who are also directors of the charity for the purposes of the Companies Act) present their report and accounts for the year ended 31 March 2023.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

Objectives and activities

The charity's objects are specifically restricted to the advancement of health for the public benefit by promoting care for those with haemoglobin disorders and study and research in haemoglobin disorders and the publication of useful results.

The charity will continue to provide peer review and conduct courses for the advancement of the health profession on the subject of the blood disorders, sickle cell disease and thalassaemia.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The charity undertook the following activities:

Peer Review

The revised Peer review standards have built the frame work for the next cycle of peer reviews. A Peer review lead Dr Emma Drasar has been appointed and has now along with her deputy leads initiated the peer review programme. The plan is to undertake a paper based assessments and then physical site visit. The administration/logistic support for the peer review programme will be provided by an external company who will be contracted to do this. The remainder of the expenses for the peer review including support for inspection leads to write the inspection reports will be funded through the fees being charged to the hospitals for the peer review. The physical inspection of sites is expected to take place over 2 years with the first inspection planned to take place in Autumn 2023.

Educational meetings

The following educational meetings were organised during the year:

May 2022: 53rd Educational Meeting: This meeting was held on 18th May and was a hybrid meeting with face to face and virtual audience and was hugely successful in partnership with the Hartley Taylor team LTD (04029300) to provide educational meeting and secretarial support. The meeting included a broad range of topics including genomics testing, the BSH pregnancy in sickle cell disorders and iron chelation guidelines. The afternoon included our first international speaker for several years talking about new therapeutic agent crizanlizumab and an update on the NHSE BLT policy for sickle cell disease, and an introduction to the new race and health observatory sickle cell lead. Our Patient society colleague spoke about concordance to chelation treatment and we bid farewell to Dr Jo Howard who has resigned from the UKFHD committee.

Nov 2022: The 54th meeting was held on 23rd November and was also a hybrid meeting at Cavendish Conference centre and on line. This meeting was primarily focused on updates from key groups supporting care for patients with haemoglobinopathies' and included updates on the peer review programme, the National haemoglobinopathy registry, the National haemoglobinopathy panel and the Race and Health Observatory. There were presentations on learning from the APPG report and the afternoon included a presentation by the UKTS

Both academic meetings had excellent feedback from attendees.

Website and rebranding:

The website was redesigned to reflect a more modern look and the redesigned UKFHD logo was approved for use by the committee.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2023

Trustee and committee meetings

Four trustee / committee meetings were held in March, June, September and December.

Liaison and attendance with other committees (feedback to Trustees via rolling agenda)

National Screening Committee: committee members attended quarterly meetings. This committee promotes the antenatal and neonatal screening programme for haemoglobinopathies.

National Haemoglobinopathy Registry: committee members attended the quarterly steering group meetings to support the work of the NHR.

Clinical Reference Group for Haemoglobinopathies: committee members attended quarterly meetings to represent the views of health professionals in the development of services for patients with Haemoglobinopathies. We also worked with the CRG on the service review and on production of policies. The Sickle cell Bone marrow transplantation policy and thalassaemia bone marrow transplant policies and iron chelation policies were all worked upon in this financial year.

APPG for sickle: Committee members attended meetings following the publishing of the No ones Listening report to help advocate/support improvements in patient care in England.

Research

Committee members attend the meeting of the non-malignant clinical research network (CRN). This national body supports research and the UK Forum promotes research into haemoglobin disorders by liaison with this group. The committee members have developed the UKHFD research subgroup as a collaborative group with colleagues nationally and have worked to support data collection on patients with haemoglobinopathies and rarer anaemias and Covid 19 infections during the pandemic.

Achievements and performance

The organisation of the above activity demonstrates the achievements of the charity during the year.

Financial review

The principal source of funding is from voluntary donations from individual and other organisations.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution. It will also try to increase the incoming level of donation.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2023

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 10th March 2015 and registered as charity on 28th September 2015 with Registered Charity No 11633743. The company was established under Memorandum of Association, which established the objects and powers of the charitable company and is governed under its Articles of Association. Teresa Baines and Claire Gillson have joined committee as representatives of NHSBT. Professor Paul Telfer has resigned as vice chair in December 2022. New committee members joining Dr Emma Drasar, Dr Joe Sharif, Dr Indu Thakur, Dr Melanie Percy, Dr Coleen Williamson and Dr Ruth Anderson. 3 New trustees are appointed March 2023: Dr Asad Luqmani, Dr Ruth Anderson and Dr Annette Blackmore.

The trustees and who served during the year and subsequently were:

Dr Baba Inusa	
Dr Mary Petrou	
Dr Farrukh Shah (Chairwoman)	
Dr Paul Telfer (Vice Chairman)	(Resigned 8 March 2023)
Dr Joanna Howard	(Resigned 31 May 2022)
Mrs Karen Madgwick (Secretary)	
Ms Helen de Marco	(Resigned 8 March 2023)
Dr Rachel Kesse-Adu (Treasurer)	
Dr Subarna Chakravorty	
Dr A Lugmani	(Appointed 8 March 2023)
Dr R Anderson	(Appointed 8 March 2023)
A Blackmore	(Appointed 8 March 2023)

The trustees are selected for their understanding and sympathy with the aim and objective of the charity, who are prepared to offer their time and expertise to support it.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity does not provide the trustees with any indemnity insurance.

The trustees meet on a regular basis to agree the strategic direction and the policy of the charity. One of the trustee is responsible for the day to day administration to ensure that the charity can deliver timely and efficient service.

There are no connected charities.

The trustees' report was approved by the Board of Trustees.

Dr Rachel Kesse-Adu (Treasurer)

Trustee

Dated: 14 December 2023

UK FORUM ON HAEMOGLOBIN DISORDERS

CHARTERED ACCOUNTANT ACCOUNTANTS' REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of UK Forum on Haemoglobin Disorders for the year ended 31 March 2023, which comprise the statement of financial activities and the related notes from the charity's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at <https://www.icaew.com/regulation>.

This report is made to the charity's trustees, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of UK Forum on Haemoglobin Disorders and state those matters that we have agreed to state to the charity's trustees, as a body, in this report in accordance with ICAEW Technical Release 07/16. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than UK Forum on Haemoglobin Disorders and the charity's trustees as a body, for our work or for this report.

It is your duty to ensure that UK Forum on Haemoglobin Disorders has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and surplus of UK Forum on Haemoglobin Disorders. You consider that UK Forum on Haemoglobin Disorders is exempt from the statutory audit requirement for the year, and is not required to obtain an independent examiner's report.

We have not been instructed to carry out an audit or a review of the financial statements of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Lyons Leonidou
Chartered Accountant Accountants

.....

Galla House
695 High Road
North Finchley
London
N12 0BT

UK FORUM ON HAEMOGLOBIN DISORDERS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes						
Income from:							
Donations and legacies	3	2,037	-	2,037	1,302	-	1,302
Charitable activities	4	47,250	-	47,250	31,238	-	31,238
Investments	5	49	-	49	1	-	1
Total income		49,336	-	49,336	32,541	-	32,541
<u>Charitable activities</u>							
Heading #ac982	6	49,210	-	49,210	25,702	-	25,702
Net income and movement in funds		126	-	126	6,839	-	6,839
Reconciliation of funds:							
Fund balances at 1 April 2022		163,873	126,505	290,378	157,034	126,505	283,539
Fund balances at 31 March 2023		163,999	126,505	290,504	163,873	126,505	290,378

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

UK FORUM ON HAEMOGLOBIN DISORDERS

BALANCE SHEET

AS AT 31 MARCH 2023

	Notes	2023 £	£	2022 £	£
Current assets					
Cash at bank and in hand		292,700		294,375	
Creditors: amounts falling due within one year	11	<u>2,196</u>		<u>3,997</u>	
Net current assets			<u>290,504</u>		<u>290,378</u>
The funds of the charity					
Restricted income funds	12		126,505		126,505
Unrestricted funds			<u>163,999</u>		<u>163,873</u>
			<u>290,504</u>		<u>290,378</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 14 December 2023

Dr Rachel Kesse-Adu (Treasurer)

Trustee

Company registration number 09481209 (England and Wales)

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2023

1 Accounting policies

Charity information

UK Forum on Haemoglobin Disorders is a private company limited by guarantee incorporated in England and Wales. The registered office is Galla House, 695 High Road, North Finchley, London, N12 0BT.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

1 Accounting policies

(Continued)

1.5 Resources expended

Resources expended on charitable expenditure comprise in meeting the charitable objective. Such cost includes direct cost of the charitable activities together with those identifiable support cost incurred that enable these activities to be undertaken.

Governance cost and support cost are cost incurred for the management and administration of the Charity. These cost are incurred so that the Charity can operate and meet its statutory and constitutional obligation.

Support cost is allocated where appropriate to an activity based on use of resource. Staff cost where appropriate has been allocated on a consistent basis.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.7 General Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees to further the objectives of the Charity. Investment income and gains are allocated to unrestricted funds.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and subscriptions

	2023	2022
	£	£
Membership fees	2,037	1,302
	<u>2,037</u>	<u>1,302</u>

4 Income from charitable activities

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Heading #ac989		
Course fees and sponsorship for the course	47,250	31,238
	<u>47,250</u>	<u>31,238</u>

5 Income from investments

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Interest receivable	49	1
	<u>49</u>	<u>1</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

6 Expenditure on charitable activities

	2023 £	2022 £
Direct costs		
Course costs - Hiring hall, catering and lecturers fees	46,471	22,510
Peer review	-	501
	<u>46,471</u>	<u>23,011</u>
Share of support and governance costs (see note 7)		
Governance	2,739	2,691
	<u>49,210</u>	<u>25,702</u>
Analysis by fund		
Unrestricted funds	<u>49,210</u>	<u>25,702</u>

7 Support costs

	Support costs £	Governance costs £	2023 £	2022 £
Legal and professional	-	2,196	2,196	2,125
General expense	-	543	543	566
	<u>-</u>	<u>2,739</u>	<u>2,739</u>	<u>2,691</u>
Analysed between				
Charitable activities	<u>-</u>	<u>2,739</u>	<u>2,739</u>	<u>2,691</u>

Governance costs includes Accountancy fees of £2,196 (2022 £2,125).

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year or previous year, None of the trustees were reimbursed any expenses during current year or previous year.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

9 Employees

The average monthly number of employees during the year was:

2023 Number	2022 Number
8	9
<u>8</u>	<u>9</u>

There were no paid employees in the year.

10 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

11 Creditors: amounts falling due within one year

	2023 £	2022 £
Accruals	2,196	3,997
	<u>2,196</u>	<u>3,997</u>

12 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations held on trust for specific purposes:

	At 1 April 2022 £	At 31 March 2023 £
	126,505	126,505
	<u>126,505</u>	<u>126,505</u>
Previous year:	At 1 April 2021 £	At 31 March 2022 £
Peer review	126,505	126,505
	<u>126,505</u>	<u>126,505</u>

Restricted funds should be applied for quality peer review programme and work on quality assurances for brain vessel scans for children with sickle cell disease.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 April 2022 £	Incoming resources £	Resources expended £	At 31 March 2023 £
General funds	163,873	49,336	(49,210)	163,999
Previous year:	At 1 April 2021 £	Incoming resources £	Resources expended £	At 31 March 2022 £
General funds	157,034	32,541	(25,702)	163,873

14 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total £
Fund balances at 31 March 2023 are represented by:			
Current assets	290,504	-	290,504
	290,504	-	290,504

UK FORUM ON HAEMOGLOBIN DISORDERS

England & Wales - Charity number 1163743

Accounts

Charity registration number 1163743

Company registration number 09481209 (England and Wales)

UK FORUM ON HAEMOGLOBIN DISORDERS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

UK FORUM ON HAEMOGLOBIN DISORDERS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Dr Baba Inusa
Dr Mary Petrou
Dr Farrukh Shah
Dr Paul Telfer
Mrs Karen Madgwick
Ms Helen de Marco
Dr Rachel Kesse-Adu
Dr Subarna Chakravorty

Charity number

1163743

Company number

09481209

Registered office

Galla House
695 High Road
North Finchley
London
N12 0BT

Accountants

Lyons Leonidou
Galla House
695 High Road
North Finchley
London
N12 0BT

Bankers

National Westminster Bank Plc
Queen Street Branch
96 Queen Street
Cardiff
CF10 2GR

UK FORUM ON HAEMOGLOBIN DISORDERS

CONTENTS

	Page
Trustees' report	1 - 4
Accountants' report	5
Statement of financial activities	6
Balance sheet	7
Notes to the financial statements	8 - 12

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2022

The trustees (who are also directors of the charity for the purposes of the Companies Act) present their report and accounts for the year ended 31 March 2022.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

Objectives and activities

The charity's objects are specifically restricted to the advancement of health for the public benefit by promoting care for those with haemoglobin disorders and study and research in haemoglobin disorders and the publication of useful results.

The charity will continue to provide peer review and conduct courses for the advancement of the health profession on the subject of the blood disorders, sickle cell disease and thalassaemia.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2022

The charity undertook the following activities:

Peer Review

The new commissioning framework with SHT and HCC structure led to the decision to revise the Peer review standards in preparation for another cycle. A multi professional group including patient representatives from patient societies reviewed and amended the previously used standards. The UKFHD commissioned 2 colleagues who had previously worked on the West Midlands Quality review (Jane Eminson and assistant) to help and provide administrative support with the revision of the standards. The revised standards were then sent out for consultation to the membership and wider NHS haemoglobinopathy representatives and then finalised. The revised standards were presented at the educational meeting in November 2021.

Educational meetings

The following educational meetings were organised during the year:

May 2021: 51st Educational Meetings - This meeting was held virtually and was hugely successful in partnership with the Hartley Taylor team LTD (04029300) to provide educational meeting and secretarial support. The programme covered presentations relating to the covid 19 pandemic, how haemoglobinopathy patients were faring and management of complications related to covid 19 infection in sickle cell disease. There was a panel discussion on novel therapies including the new commissioning plans for bone marrow transplantation in sickle cell.

Nov 2021: The 52nd meeting was held on 17th November and covered a range of topics (virtual meeting) on peer review standards, the national haemoglobinopathy registry, lessons learnt from the first year of National Haemoglobinopathy Panel and race relations and health inequalities.

Both meetings had excellent attendance and feedback

Trustee and committee meetings

Four trustee / committee meetings were held in March, June, September and December.

Liaison with other committees

Liaison and attendance with other committees (feedback to Trustees via rolling agenda)

National Screening Committee:

Committee members attended quarterly meetings. This committee promotes the antenatal and neonatal screening programme for haemoglobinopathies.

National Haemoglobinopathy Registry:

Committee members attended the quarterly steering group meetings to support the work of the NHR.

Clinical Reference Group for Haemoglobinopathies:

Committee members attended quarterly meetings to represent the views of health professionals in the development of services for patients with Haemoglobinopathies. We also worked with the CRG on the service review and on production of policies. The Sickle cell Bone marrow transplantation policy and thalassaemia bone marrow transplant policies and iron chelation policies were all worked upon in this financial year.

Research

Committee members attend the meeting of the non-malignant clinical research network (CRN). This national body supports research and the UK Forum promotes research into haemoglobin disorders by liaison with this group. The committee members have developed the UKHFD research subgroup as a collaborative group with colleagues nationally and have worked to support data collection on patients with haemoglobinopathies and rarer anaemias and Covid 19 infections during the pandemic

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2022

Achievements and performance

The organisation of the above activity demonstrates the achievements of the charity during the year.

Financial review

The principal source of funding is from voluntary donations from individual and other organisations.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution. It will also try to increase the incoming level of donation.

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 10th March 2015 and registered as charity on 28th September 2015 with Registered Charity No 11633743. The company was established under Memorandum of Association, which established the objects and powers of the charitable company and is governed under its Articles of Association.

The trustees and who served during the year and subsequently were:

Dr Baba Inusa	
Dr Mary Petrou	
Dr Farrukh Shah	
Dr Paul Telfer	
Dr Joanna Howard	(Resigned 31 May 2022)
Dr Iyabode Oni	(Resigned 31 December 2021)
Mrs Karen Madgwick	
Ms Helen de Marco	
Dr Rachel Kesse-Adu	
Dr Subarna Chakravorty	

The trustees are selected for their understanding and sympathy with the aim and objective of the charity, who are prepared to offer their time and expertise to support it.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity does not provide the trustees with any indemnity insurance.

The trustees meet on a regular basis to agree the strategic direction and the policy of the charity. One of the trustee is responsible for the day to day administration to ensure that the charity can deliver timely and efficient service.

There are no connected charities.

The trustees' report was approved by the Board of Trustees.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 MARCH 2022



Dr Rachel Kesse-Adu

Trustee

Dated: 21 December 2022

UK FORUM ON HAEMOGLOBIN DISORDERS

CHARTERED ACCOUNTANT ACCOUNTANTS' REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2022

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of UK Forum on Haemoglobin Disorders for the year ended 31 March 2022, which comprise the statement of financial activities and the related notes from the charity's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at <https://www.icaew.com/regulation>

This report is made to the charity's trustees, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of UK Forum on Haemoglobin Disorders and state those matters that we have agreed to state to the charity's trustees, as a body, in this report in accordance with ICAEW Technical Release 07/16. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than UK Forum on Haemoglobin Disorders and the charity's trustees as a body, for our work or for this report.

It is your duty to ensure that UK Forum on Haemoglobin Disorders has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and surplus of UK Forum on Haemoglobin Disorders. You consider that UK Forum on Haemoglobin Disorders is exempt from the statutory audit requirement for the year, and is not required to obtain an independent examiner's report.}

We have not been instructed to carry out an audit or a review of the financial statements of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Lyons Leonidou

22 December 2022

Chartered Accountant Accountants

Galla House
695 High Road
North Finchley
London
N12 0BT

UK FORUM ON HAEMOGLOBIN DISORDERS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Total Unrestricted funds 2022 £	Restricted funds 2021 £	Total 2021 £
Income from:						
Donations and subscriptions	3	1,302	-	1,302	241	241
Charitable activities	4	31,238	-	31,238	43,330	43,330
Investments	5	1	-	1	5	5
Total income		32,541	-	32,541	43,576	43,576
Expenditure on:						
Charitable activities	6	25,702	-	25,702	31,273	31,273
Total charitable expenditure		25,702	-	25,702	31,273	31,273
Net income for the year/ Net movement in funds		6,839	-	6,839	12,303	12,303
Fund balances at 1 April 2021		157,034	126,505	283,539	144,731	271,236
Fund balances at 31 March 2022		163,873	126,505	290,378	157,034	283,539

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

UK FORUM ON HAEMOGLOBIN DISORDERS

BALANCE SHEET

AS AT 31 MARCH 2022

	Notes	2022 £	£	2021 £	£
Current assets					
Cash at bank and in hand		294,375		287,536	
Creditors: amounts falling due within one year					
	10	(3,997)		(3,997)	
Net current assets			<u>290,378</u>		<u>283,539</u>
Income funds					
Restricted funds	11	126,505		126,505	
Unrestricted funds		163,873		157,034	
			<u>290,378</u>		<u>283,539</u>


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2022.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 21 December 2022


Dr Rachel Kesse-Adu
Trustee

Company registration number 09481209

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

Charity Information

UK Forum on Haemoglobin Disorders is a private company limited by guarantee incorporated in England and Wales. The registered office is , Galla House, 695 High Road, North Finchley, London, N12 0BT.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

(Continued)

1.5 Resources expended

Resources expended on charitable expenditure comprise in meeting the charitable objective. Such cost includes direct cost of the charitable activities together with those identifiable support cost incurred that enable these activities to be undertaken.

Governance cost and support cost are cost incurred for the management and administration of the Charity. These cost are incurred so that the Charity can operate and meet its statutory and constitutional obligation.

Support cost is allocated where appropriate to an activity based on use of resource. Staff cost where appropriate has been allocated on a consistent basis.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.7 General Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees to further the objectives of the Charity. Investment income and gains are allocated to unrestricted funds.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and subscriptions

	2022	2021
	£	£
Membership fees	1,302	241
	<u>1,302</u>	<u>241</u>

4 Charitable activities

	Course fees 2022	Course fees 2021
	£	£
Course fees and sponsorship for the course	31,238	43,330
	<u>31,238</u>	<u>43,330</u>

5 Investments

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Interest receivable	1	5
	<u>1</u>	<u>5</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

6 Charitable activities

	2022	2021
	£	£
Course costs - Hiring hall, catering and lecturers fees	22,510	24,566
Education support	-	4,147
Peer review	501	-
	<u>23,011</u>	<u>28,713</u>
Share of governance costs (see note 7)	2,691	2,560
	<u>25,702</u>	<u>31,273</u>

7 Support costs

	Support costs	Governance costs	2022	2021
	£	£	£	£
Legal and professional	-	2,125	2,125	1,998
General expense	-	566	566	562
	<u>-</u>	<u>2,691</u>	<u>2,691</u>	<u>2,560</u>
Analysed between Charitable activities	<u>-</u>	<u>2,691</u>	<u>2,691</u>	<u>2,560</u>

Governance costs includes Accountancy fees of £1998 (2021 £1,998).

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year or previous year, None of the trustees were reimbursed any expenses during current year or previous year.

9 Employees

The average monthly number of employees during the year was:

	2022	2021
	Number	Number
Total	<u>-</u>	<u>-</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

9 Employees (Continued)

There were no employees whose annual remuneration was more than £60,000.

10 Creditors: amounts falling due within one year

	2022 £	2021 £
Accruals	<u>3,997</u>	<u>3,997</u>

11 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations held on trust for specific purposes:

	Movement in funds		Movement in funds		Balance at 31 March 2022
	Balance at 1 April 2020 £	Incoming resources £	Balance at 1 April 2021 £	Incoming resources £	
Peer review	<u>126,505</u>	<u>-</u>	<u>126,505</u>	<u>-</u>	<u>126,505</u>

Restricted funds should be applied for quality peer review programme and work on quality assurances for brain vessel scans for children with sickle cell disease.

12 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total £
Fund balances at 31 March 2022 are represented by:			
Current assets	<u>290,378</u>	<u>-</u>	<u>290,378</u>
	<u>290,378</u>	<u>-</u>	<u>290,378</u>

Accounts

Charity Registration No. 1163743

Company Registration No. 09481209 (England and Wales)

UK FORUM ON HAEMOGLOBIN DISORDERS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

UK FORUM ON HAEMOGLOBIN DISORDERS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Dr Baba Inusa
Dr Mary Petrou
Dr Farrukh Shah
Dr Paul Telfer
Mr Neill Westerdale
Dr Joanna Howard
Dr Iyabode Oni
Mrs Karen Madgwick
Ms Helen de Marco
Dr Rachel Kesse-Adu
Dr Subarna Chakravorty

Charity number

1163743

Company number

09481209

Registered office

Galla House
695 High Road
North Finchley
London
N12 0BT

Accountants

Lyons Leonidou
Galla House
695 High Road
North Finchley
London
N12 0BT

Bankers

National Westminster Bank Plc
Queen Street Branch
96 Queen Street
Cardiff
CF10 2GR

UK FORUM ON HAEMOGLOBIN DISORDERS

CONTENTS

	Page
Trustees' report	1 - 3
Accountants' report	4
Statement of financial activities	5
Balance sheet	6
Notes to the financial statements	7 - 11

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2021

The trustees (who are also directors of the charity for the purposes of the Companies Act) present their report and accounts for the year ended 31 March 2021.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's governing document, the Companies Act 2006 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

Objectives and activities

The charity's objects are specifically restricted to the advancement of health for the public benefit by promoting care for those with haemoglobin disorders and study and research in haemoglobin disorders and the publication of useful results.

The charity will continue to provide peer review and conduct courses for the advancement of the health profession on the subject of the blood disorders, sickle cell disease and thalassaemia.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The charity undertook the following activities:

Peer Review

The UK Forum continues to support the National Peer Review for Haemoglobin Disorders. In 2018/19 it has supported self certification/self appraisal against Quality Standards. Peer review visits commenced in 2019 and were completed for all but 3 sites which were halted due to Covid 19 Pandemic in 2020. The report for Peer review cycle was completed in 2020 and presented at the British Society for haematology annual meeting which was held in April 2021 as a virtual meeting.

Educational meetings

The following educational meetings were organised during the year:

May 2020: 50th Educational Meeting - 'Celebrating 25 years' was cancelled due to lock down during the first wave of covid 19. The meeting cancellation incurred a charge from the conference centre for the booking. This May meeting was rescheduled and eventually held 12th November as a virtual meeting.

The trustees commissioned Hartley Taylor LTD (04029300) to provide educational meeting and secretarial support from 2019. This has continued throughout 2020.

Liaison with other committees

Clinical Reference Group for Haemoglobinopathies: committee members attended quarterly meetings to represent the views of health professionals in the development of services for patients with Haemoglobinopathies. We also worked with the CRG on the service review and on production of policies.

National Screening Committee: committee members attended quarterly meetings. This committee promotes the antenatal and neonatal screening programme for haemoglobinopathies.

National Haemoglobinopathy Registry: committee members attended the quarterly steering group meetings to represent the views of health professionals in the development of the national registry and to promote care for those with haemoglobin disorders.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2021

Research

Committee members attend the meeting of the non-malignant clinical research network (CRN). This national body supports research and the UK Forum promotes research into haemoglobin disorders by liaison with this group. The committee members have developed the UKHFD research subgroup as a collaborative group with colleagues nationally and have worked to support data collection on patients with haemoglobinopathies and rarer anaemias and Covid 19 infections during the pandemic. This has resulted in several successful research papers on covid 19 as well as presentations at International meetings.

Transcranial Doppler scanning for primary stroke prevention Work on the Quality Assurance for TCDs and how to embed this into clinical practice continued during 2020 but is now overseen by the National haemoglobinopathy panel. Funds are still held for TCD QA work.

Achievements and performance

The organisation of the above activity demonstrates the achievements of the charity during the year.

Financial review

The principal source of funding is from voluntary donations from individual and other organisations.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees considers that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

The charity will continue to meet the objectives of its constitution. It will also try to increase the incoming level of donation,

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 10th March 2015 and registered as charity on 28th September 2015 with Registered Charity No 11633743. The company was established under Memorandum of Association , which established the objects and powers of the charitable company and is governed under its Articles of Association.

The trustees and who served during the year and subsequently were:

Dr Baba Inusa

Dr Mary Petrou

Dr Farrukh Shah

Dr Paul Telfer

Mr Neill Westerdale

Dr Joanna Howard

Dr Iyabode Oni

Mrs Karen Madgwick

Ms Helen de Marco

Dr Rachel Kesse-Adu

Dr Subarna Chakravorty

The trustees are selected for their understanding and sympathy with the aim and objective of the charity, who are prepared to offer their time and expertise to support it.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

UK FORUM ON HAEMOGLOBIN DISORDERS

TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 MARCH 2021

The charity does not provide the trustees with any indemnity insurance.

The trustees meet on a regular basis to agree the strategic direction and the policy of the charity. One of the trustee is responsible for the day to day administration to ensure that the charity can deliver timely and efficient service.

There are no connected charities.

The trustees' report was approved by the Board of Trustees.



.....
Dr Rachel Kesse-Adu

Trustee

Dated: 22 December 2021

UK FORUM ON HAEMOGLOBIN DISORDERS

CHARTERED ACCOUNTANT ACCOUNTANTS' REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2021


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of UK Forum on Haemoglobin Disorders for the year ended 31 March 2021, which comprise the statement of financial activities and the related notes from the charity's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at <https://www.icaew.com/regulation>

This report is made to the charity's trustees, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of UK Forum on Haemoglobin Disorders and state those matters that we have agreed to state to the charity's trustees, as a body, in this report in accordance with ICAEW Technical Release 07/16. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than UK Forum on Haemoglobin Disorders and the charity's trustees as a body, for our work or for this report.

It is your duty to ensure that UK Forum on Haemoglobin Disorders has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and surplus of UK Forum on Haemoglobin Disorders. You consider that UK Forum on Haemoglobin Disorders is exempt from the statutory audit requirement for the year, and is not required to obtain an independent examiner's report.}

We have not been instructed to carry out an audit or a review of the financial statements of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Lyons Leonidou

23 December 2021

Chartered Accountant Accountants

Galla House
695 High Road
North Finchley
London
N12 0BT

UK FORUM ON HAEMOGLOBIN DISORDERS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Income from:							
Donations and subscriptions	3	241	-	241	1,290	-	1,290
Charitable activities	4	43,330	-	43,330	42,660	-	42,660
Investments	5	5	-	5	22	-	22
Total income		43,576	-	43,576	43,972	-	43,972
Expenditure on:							
<u>Charitable activities</u>	6	31,273	-	31,273	27,066	-	27,066
Total charitable expenditure		31,273	-	31,273	27,066	-	27,066
Net income for the year/ Net movement in funds		12,303	-	12,303	16,906	-	16,906
Fund balances at 1 April 2020		144,731	126,505	271,236	127,825	126,505	254,330
Fund balances at 31 March 2021		157,034	126,505	283,539	144,731	126,505	271,236

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

UK FORUM ON HAEMOGLOBIN DISORDERS

BALANCE SHEET

AS AT 31 MARCH 2021

	Notes	2021 £	£	2020 £	£
Current assets					
Cash at bank and in hand		287,536		290,233	
Creditors: amounts falling due within one year	10	(3,997)		(18,997)	
Net current assets			<u>283,539</u>		<u>271,236</u>
Income funds					
Restricted funds	12		126,505		126,505
Unrestricted funds			157,034		144,731
			<u>283,539</u>		<u>271,236</u>


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2021.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 22 December 2021



Dr Rachel Kesse-Adu
Trustee

Company Registration No. 09481209

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

Charity information

UK Forum on Haemoglobin Disorders is a private company limited by guarantee incorporated in England and Wales. The registered office is, Galla House, 695 High Road, North Finchley, London, N12 0BT.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

(Continued)

1.5 Resources expended

Resources expended on charitable expenditure comprise in meeting the charitable objective. Such cost includes direct cost of the charitable activities together with those identifiable support cost incurred that enable these activities to be undertaken.

Governance cost and support cost are cost incurred for the management and administration of the Charity. These cost are incurred so that the Charity can operate and meet its statutory and constitutional obligation.

Support cost is allocated where appropriate to an activity based on use of resource. Staff cost where appropriate has been allocated on a consistent basis.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.7 General Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees to further the objectives of the Charity. Investment income and gains are allocated to unrestricted funds.

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and subscriptions

	2021	2020
	£	£
Membership fees	241	1,290
	<u>241</u>	<u>1,290</u>

4 Charitable activities

	Course fees 2021	Course fees 2020
	£	£
Course fees and sponsorship for the course	43,330	57,660
Less: deferred income	-	(15,000)
	<u>43,330</u>	<u>42,660</u>

5 Investments

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Interest receivable	5	22
	<u>5</u>	<u>22</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

6 Charitable activities

	2021 £	2020 £
Course costs - Hiring hall, catering and lecturers fees	24,566	18,843
Education support	4,147	5,044
	<u>28,713</u>	<u>23,887</u>
Share of governance costs (see note 7)	2,560	3,179
	<u>31,273</u>	<u>27,066</u>

7 Support costs

	Support costs £	Governance costs £	2021 £	2020 £
Legal and professional	-	1,998	1,998	2,606
General expense	-	562	562	573
	<u>-</u>	<u>2,560</u>	<u>2,560</u>	<u>3,179</u>
Analysed between Charitable activities	<u>-</u>	<u>2,560</u>	<u>2,560</u>	<u>3,179</u>

Governance costs includes Accountancy fees of £1998 (2020 £2,606).

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year, One (2020 : one) trustee (2020 trustee) was/ (2020 was) reimbursed for Conference cost of £50 (2020 ; £85).

9 Employees

The average monthly number of employees during the year was:

	2021 Number	2020 Number
Total	<u>-</u>	<u>-</u>

UK FORUM ON HAEMOGLOBIN DISORDERS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

9 Employees

(Continued)

There were no employees whose annual remuneration was more than £60,000.

10 Creditors: amounts falling due within one year

	Notes	2021 £	2020 £
Deferred income	11	-	15,000
Accruals		3,997	3,997
		<u>3,997</u>	<u>18,997</u>

11 Deferred income

	2021 £	2020 £
Other deferred Income	-	15,000
	<u>-</u>	<u>15,000</u>

12 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations held on trust for specific purposes:

	Movement in funds		Movement in funds		Balance at 31 March 2021 £
	Balance at 1 April 2019 £	Incoming resources £	Balance at 1 April 2020 £	Incoming resources £	
Peer review	<u>126,505</u>	<u>-</u>	<u>126,505</u>	<u>-</u>	<u>126,505</u>

Restricted funds should be applied for quality peer review programme and work on quality assurances for brain vessel scans for children with sickle cell disease.

13 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total £
Fund balances at 31 March 2021 are represented by:			
Current assets	283,539	-	283,539
	<u>283,539</u>	<u>-</u>	<u>283,539</u>